Adaptive Biotechnologies Corp (NAS:ADPT)
$ 3.65 0.21 (6.1%) Market Cap: 537.89 Mil Enterprise Value: 294.57 Mil PE Ratio: 0 PB Ratio: 1.95 GF Score: 72/100

Adaptive Biotechnologies Corp at Jefferies Healthcare Conference (Virtual) Transcript

Jun 04, 2020 / 05:00PM GMT
Release Date Price: $39.2 (-1.16%)
Brandon Couillard
Jefferies LLC, Research Division - Equity Analyst

Hi, everyone. I'm Brandon Couillard, senior life science tools and diagnostics analyst at Jefferies. It's my pleasure to introduce Chad Robins, the CEO and Co-founder of Adaptive Biotech, to present at the Jefferies Virtual Healthcare Conference.

Chad, I'll turn it over to you.

Chad M. Robins
Adaptive Biotechnologies Corporation - Co-Founder, CEO & Chairman

Hey, thanks so much, Brandon.

I'm Chad Robins, I'm the CEO of Adaptive Biotechnologies.

I'll remind you briefly of the safe harbor.

My brother, Harlan and I started Adaptive a decade ago on the premise that if we could learn how to read and translate the genetics of the adaptive immune system, we could create clinical products that could both diagnose and treat disease. We believed that the immune system represents the largest clinical applications of genomics. The reason is because your immune system both detects and treats almost all diseases in the exact same way, whether they be cancer,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot